This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Naftopidil
Accession Number
DB12092
Type
Small Molecule
Groups
Investigational
Description

Naftopidil has been investigated for the treatment of Disorder of Urinary Stent.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
R9PHW59SFN
CAS number
57149-07-2
Weight
Average: 392.499
Monoisotopic: 392.20999277
Chemical Formula
C24H28N2O3
InChI Key
HRRBJVNMSRJFHQ-UHFFFAOYSA-N
InChI
InChI=1S/C24H28N2O3/c1-28-24-11-5-4-10-22(24)26-15-13-25(14-16-26)17-20(27)18-29-23-12-6-8-19-7-2-3-9-21(19)23/h2-12,20,27H,13-18H2,1H3
IUPAC Name
1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-(naphthalen-1-yloxy)propan-2-ol
SMILES
COC1=CC=CC=C1N1CCN(CC(O)COC2=CC=CC3=CC=CC=C23)CC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Naftopidil is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Naftopidil is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Naftopidil is combined with 4-hydroxycoumarin.
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Naftopidil.
AbciximabNaftopidil may increase the anticoagulant activities of Abciximab.
AcebutololAcebutolol may increase the hypotensive activities of Naftopidil.
AceclofenacThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Aceclofenac.
AcemetacinThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Naftopidil is combined with Acenocoumarol.
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Naftopidil.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
4418
PubChem Substance
347828396
ChemSpider
4265
BindingDB
50773
ChEBI
31891
ChEMBL
CHEMBL142635
Wikipedia
Naftopidil

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers1
3CompletedTreatmentDisorder of Urinary Stent1
3CompletedTreatmentUreter Stones1
3Unknown StatusTreatmentHyperplasia1
4CompletedTreatmentLower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia1
4Unknown StatusTreatmentRenal Stones / Ureter Calculi1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0699 mg/mLALOGPS
logP3.65ALOGPS
logP3.77ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)14.08ChemAxon
pKa (Strongest Basic)7.35ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area45.17 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity115.96 m3·mol-1ChemAxon
Polarizability44.37 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-0940000000-0343a26091ec3a7f543c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-0849000000-feac1b69e7ec5e9d12d5
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-1940000000-2c5b43ec0ae8e30b33df

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Naphthalenes / Methoxyanilines / Aminophenyl ethers / Phenoxy compounds / Methoxybenzenes / Dialkylarylamines / Anisoles / N-alkylpiperazines / Alkyl aryl ethers
show 6 more
Substituents
N-arylpiperazine / Phenylpiperazine / Naphthalene / Aminophenyl ether / Methoxyaniline / Phenoxy compound / Anisole / Phenol ether / Methoxybenzene / Aniline or substituted anilines
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Uesawa Y, Takeuchi T, Mohri K: Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. [PubMed:22039822]

Drug created on October 20, 2016 15:20 / Updated on October 01, 2018 15:09